Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Autor: Lundin J; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden.; Lymphoma Unit, Department of Hematology Karolinska University Hospital Solna Stockholm Sweden., Mulder TA; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden., Kättström M; Department of Medicine, Section of Hematology Örebro University Hospital Örebro Sweden., Wästerlid T; Lymphoma Unit, Department of Hematology Karolinska University Hospital Solna Stockholm Sweden.; Division of Clinical Epidemiology, Department of Medicine Solna Karolinska Institutet Stockholm Sweden., Uddevik A; Department of Medicine, Section of Hematology Gävle Hospital Gävle Sweden., Mellstedt H; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden., Heimersson K; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden., Hansson L; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden.; Lymphoma Unit, Department of Hematology Karolinska University Hospital Solna Stockholm Sweden., Palma M; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden.; Lymphoma Unit, Department of Hematology Karolinska University Hospital Solna Stockholm Sweden., Österborg A; Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden.; Lymphoma Unit, Department of Hematology Karolinska University Hospital Solna Stockholm Sweden.

Publikováno v: EJHaem [EJHaem] 2021 Jul 14; Vol. 2 (3), pp. 525-529. Date of Electronic Publication: 2021 Jul 14 (Print Publication: 2021).